VOGELXO Drug Patent Profile

When do Vogelxo patents expire, and when can generic versions of Vogelxo launch?

Vogelxo is a drug marketed by Upsher Smith Labs and is included in one NDA. There are three patents protecting this drug.

This drug has seven patent family members in seven countries.

The generic ingredient in VOGELXO is testosterone. There are sixty-nine drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vogelxo

A generic version of VOGELXO was approved as testosterone by ACTAVIS LABS UT INC on January 27^th, 2006.

Summary for VOGELXO

International Patents:	7
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	1
Patent Applications:	4,285
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for VOGELXO
What excipients (inactive ingredients) are in VOGELXO?	VOGELXO excipients list
DailyMed Link:	VOGELXO at DailyMed

See drug prices for VOGELXO

Recent Clinical Trials for VOGELXO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Upsher-Smith Laboratories	Phase 4

See all VOGELXO clinical trials

Pharmacology for VOGELXO

Drug Class	Androgen
Mechanism of Action	Androgen Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for VOGELXO

G03BA	3-oxoandrosten (4) derivatives
G03B	ANDROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for VOGELXO

VOGELXO is protected by three US patents.

Patents protecting VOGELXO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upsher Smith Labs	VOGELXO	testosterone	GEL, METERED;TRANSDERMAL	204399-003	Jun 4, 2014	BX	RX	No	No			Y
Upsher Smith Labs	VOGELXO	testosterone	GEL;TRANSDERMAL	204399-002	Jun 4, 2014	AB2	RX	No	No			Y
Upsher Smith Labs	VOGELXO	testosterone	GEL, METERED;TRANSDERMAL	204399-003	Jun 4, 2014	BX	RX	No	No			Y

EU/EMA Drug Approvals for VOGELXO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Warner Chilcott UK Ltd.	Intrinsa	testosterone	EMEA/H/C/000634 Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28
Warner Chilcott  Deutschland GmbH	Livensa	testosterone	EMEA/H/C/000630 Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28

International Patents for VOGELXO

See the table below for patents covering VOGELXO around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015089289
Australia	2014362275	Testosterone gel compositions and related methods
Taiwan	I608766